Christina Bahrs

Dr. Christina Bahrs

Jena University Hospital, Jena, Thuringia, Germany
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
STSelma Tobudic
Selma Tobudic
Christina BahrsChristina Bahrs
Christina Bahrs
HBHeinz Burgmann
Heinz Burgmann
HLHeimo Lagler
Heimo Lagler
Michael RamharterMichael Ramharter
Michael Ramharter
FTFlorian Thalhammer
Florian Thalhammer
The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.

8 December 2009 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
STSelma Tobudic
Selma Tobudic
Christina BahrsChristina Bahrs
Christina Bahrs
ALAndrea Lassnigg
Andrea Lassnigg
WGWolfgang Graninger
Wolfgang Graninger
EPElisabeth Presterl
Elisabeth Presterl
The aim of the present study was to evaluate the in vitro activity and synergism of the combinations of amphotericin B/caspofungin and amphotericin B/posaconazole against Candida albicans, grown either as planktonic cells or in biofilms. Ten C. albicans bloodstream isolates used in this study were collected from intensive care patients admitted to the Vienna University Hospital between 2006 and 2007. Chequerboard tests were employed to determine the efficacy of the antifungal combinations amphotericin B/caspofungin and amphotericin B/posaconazole against both planktonic cells and biofilms. C. albicans biofilms were prepared using the static microtitre plate model. The activity of antifungal combination therapy was determined by visual reading for planktonic cells and using the XTT assay for biofilms. For Candida biofilms the median MIC was 4 mg/L for amphotericin B and caspofungin, and >256 mg/L for posaconazole. The combination amphotericin B/posaconazole yielded synergism [fractional inhibitory concentration index (FICI) <0.26], whereas amphotericin B/caspofungin yielded indifferent interaction only (FICI 0.75–1.25) against all isolates when grown in biofilms. Under planktonic conditions, synergism was demonstrable for the combination amphotericin B/caspofungin against 4 of the 10 isolates, whereas the combination of caspofungin/posaconazole was indifferent against all tested isolates. We showed that MICs for planktonic and biofilm forms of C. albicans were much lower when treated with an antifungal combination than when treated with single agents. The combination of amphotericin B/posaconazole yielded synergism against Candida biofilms, whereas amphotericin B/caspofungin yielded indifferent interaction.

13 September 2019 in Infection
Verified
Journal Article
Open access
PDF file
STSelma Tobudic
Selma Tobudic
Christina BahrsChristina Bahrs
Christina Bahrs
HBHeinz Burgmann
Heinz Burgmann
HLHeimo Lagler
Heimo Lagler
CSChristoph Steininger
Christoph Steininger
FTFlorian Thalhammer
Florian Thalhammer
Purpose: Dalbavancin is a novel lipoglycopeptide with potent activity against several gram-positive pathogens, an excellent safety profile and a long elimination half-life. Methods: In this case series observed at the University Hospital of Vienna between 2015 and 2017, all adult patients with gram-positive infections who received at least one dosage of dalbavancin were screened (n = 118). A total of 72 patients were included in the final analysis. The number of included patients stratified by the source of infection was: skin and soft tissue infection (SSTI) (n = 26), osteomyelitis (n = 20), spondylodiscitis (n = 14), acute septic arthritis (n = 4) and prosthetic joint infection (n = 8). Results: In 46 patients (64%), clinical cure was detected at the end of dalbavancin therapy without additional antibiotic therapy. Of the 26 patients who received additional antibiotic therapy other than dalbavancin, 15 patients (21%) showed no clinical improvement under dalbavancin therapy, four patients (5%) had side effects (nausea n = 1, exanthema n = 2, hyperglycemia n = 1), and in seven patients (10%) clinical improvement under dalbavancin therapy was detected but antibiotic therapy was de-escalated to an oral drug. Conclusion: We demonstrated high clinical effectiveness of dalbavancin for acute gram-positive infections primarily acute SSTI, acute septic arthritis, acute osteomyelitis and spondylodiscitis. In patients with biofilm-associated infection (chronic infection or joint prosthesis), source control was absolutely necessary for treatment success.

1 November 2012 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
MDMagda Diab-Elschahawi
Magda Diab-Elschahawi
Christina BahrsChristina Bahrs
Christina Bahrs
FHFerry Hagen
Ferry Hagen
JMJacobus F. Meis
Jacobus F. Meis
ALAndrea M. Lassnig
Andrea M. Lassnig
CKCorné H. W. Klaassen
Corné H. W. Klaassen
Candida parapsilosis has become a significant cause of invasive fungal infections in seriously ill patients. Nosocomial outbreaks through direct and indirect contact have been described. The aim of this study was the molecular characterization of what appeared to be an ongoing C. parapsilosis outbreak at the cardiothoracic intensive care unit of the University Hospital of Vienna between January 2007 and December 2008. Using two different molecular typing methods—automated repetitive sequence-based PCR (DiversiLab; bioMérieux) and microsatellite genotyping—we investigated the genetic relationship of 99 C. parapsilosis isolates. Eighty-three isolates originated from the cardiothoracic intensive care unit, while 16 isolates were random control isolates from other intensive care units and a different Austrian hospital. The 99 C. parapsilosis isolates analyzed by repetitive-element PCR all showed identical genotypes, suggesting an ongoing outbreak. In contrast, microsatellite genotyping showed a total of 56 different genotypes. Two major genotypes were observed in 10 and 15 isolates, respectively, whereas another 13 genotypes were observed in 2 to 4 isolates each. Forty-one genotypes were observed only once. Closely related genotypes that differed in only a single microsatellite marker were grouped into clonal complexes. When it comes to C. parapsilosis , microsatellite genotyping is a more discriminative method than repetitive-element PCR genotyping to investigate outbreaks.

7 July 2016 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
NHNicole Harrison
Nicole Harrison
ABAlexandra Brand
Alexandra Brand
Christina BahrsChristina Bahrs
Christina Bahrs
STSelma Tobudic
Selma Tobudic
KBKarin Burgmann
Karin Burgmann
HBHeinz Burgmann
Heinz Burgmann
The aim of this study was to evaluate the vaccination coverage of Austrian health care workers (HCWs), their knowledge concerning the current guideline on vaccination for HCWs and their attitudes toward vaccination. A cross-sectional survey was performed by distributing 200 questionnaires among the nursing staff of several medical wards and intensive care units of the Vienna General Hospital. 116 questionnaires were returned for analysis with 77.4% female and 22.6% male participants. While certain vaccines like hepatitis B, tetanus and polio had high vaccination rates of up to 94% and good knowledge concerning the vaccination status, other vaccines like measles (59.8%), mumps (60.7%), rubella (70.5%), influenza (42.1%) or pertussis (58.2%) showed much lower coverage. The main sources of information were nursing school (59.1%), secondary school (46.1%), parents (45.2%) and media in general (45.2%). Only 21.9% of HCWs claimed to know the current guideline on vaccination. Those who knew the guideline were significantly more likely to consider certain vaccines like measles, mumps, rubella, diphtheria, polio and varicella as recommended (p ≤ 0.04). The most important reasons for receiving vaccination were self-protection (87.5%), prevention of epidemics (54.5%), protection of others (55.4%) and of patients (42.9%). Fear of side effects (67.2%), negative experiences with vaccines (22.4%), the additional doctor's appointment (20.7%) and considering vaccines as an invention by the pharmaceutical industry (19%) were hindering factors for vaccination of HCWs. Considering the essential role of HCWs in preventing diseases, this study noted a remarkable lack of information on vaccination in this profession.

1 May 2010 in Mycoses
Verified
Journal Article
Closed access
PDF file
STSelma Tobudic
Selma Tobudic
ALAndrea Lassnigg
Andrea Lassnigg
Christina BahrsChristina Bahrs
Christina Bahrs
WGWolfgang Graninger
Wolfgang Graninger
EPElisabeth Presterl
Elisabeth Presterl